Business
Directors' Interests
Directors' Interests.
About this update from Metir Plc
[{"type":"text","content":"\n \nRNS Number : 4517S Microsaic Systems plc 25 June 2018 \n\n25 June 2018\nMicrosaic Systems plc\n \n(\"Microsaic\", \"Microsaic Systems\" or the \"Company\")\n \nDirectors' Interests\n \nMicrosaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry (\"MS\") instruments, is pleased to announce that following Admission today of the Placing Shares to trading on AIM in connection with the Transaction announced on 5 and 6 June 2018, the beneficial interests of the Directors in the issued share capital of the Company and percentage interests are as follows:\n \n\n\n\nDirector\n\n\nNumber of Ordinary Shares\n\n\nPer cent. of issued share capital \n\n\n\n\nPeter Grant\n\n\n750,000\n\n\n0.16\n\n\n\n\nGlenn Tracey\n\n\n800,000\n\n\n0.18\n\n\n\n\nBevan Metcalf\n\n\n1,050,000\n\n\n0.23\n\n\n\n\nChristopher Buckley\n\n\n550,000\n\n\n0.12\n\n\n\n\nAndrew Holmes\n\n\n3,682,111\n\n\n0.81\n\n\n\n\nEric Yeatman\n\n\n4,646,632\n\n\n1.02\n\n\n\n \nThe Directors together hold an aggregate of 11,478,743 Ordinary Shares, representing 2.52 per cent. of the issued share capital of the Company. The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide additional detail.\n \nDefined terms used in this announcement will have the meanings (unless the context otherwise requires) set out in the circular dated 6 June 2018, which is available on the Company's website at http://www.microsaic.com/investors/documents/.\n \n\n\n\nEnquiries: \n \n\n\n\n\n\n\n\nMicrosaic Systems plc\nGlenn Tracey, CEO\nBevan Metcalf, FD\n\n\n+44 (0) 1483 751 577\n\n\n\n\n \nN+1 Singer (Nominated Adviser & Broker)\nShaun Dobson\nLiz Yong\n \n\n\n \n+44 (0)20 7496 3000\n\n\n\n\nIFC Advisory Ltd (Financial PR)\nGraham Herring\nHeather Armstrong\nFlorence Chandler\n\n\n+44 (0)20 3934 6630\n\n\n\n \nwww.microsaic.com \n \n \n \nAbout Microsaic Systems\nMicrosaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry (\"MS\") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the deve...